EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
Price:
12.94 USD
3.94%
Market Closed
Updated:
May 16, 2024
EyePoint Pharmaceuticals Inc
Cost of Revenue
|
EyePoint Pharmaceuticals Inc
Cost of Revenue Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Cost of Revenue
-$4.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cost of Revenue
-$26.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cost of Revenue
-$11B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cost of Revenue
-$16.3B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cost of Revenue
-$15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cost of Revenue
-$7.1B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-4%
|
See Also
What is EyePoint Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-4.6m
USD
-4.6m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Cost of Revenue amounts to -4.6m USD.
What is EyePoint Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
7%
7%
Over the last year, the Cost of Revenue growth was 44%. The average annual Cost of Revenue growth rates for EyePoint Pharmaceuticals Inc have been 7% over the past three years .
You don't have any saved screeners yet
